Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16407739 | 0.81 | SMN1; SMN2 (0.36) | CYP3A4SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL9806689 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL254353 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1152835 | 0.75 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL9806691 | 0.72 | SMN1; SMN2 (0.41) | CYP2C19SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL670857 | 0.72 | SMN1; SMN2 (0.41) | CYP2C19SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2321698 | 0.72 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL10850510 | 0.72 | SMN1; SMN2 (0.41) | CYP2C19SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL713102 | 0.71 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL11725215 | 0.71 | MEN1 (0.39) | SMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873307-B2 | Manufacture of compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873307-B2 | Manufacture of compounds and compositions for inhibiting the activity of SHP2 | PTPN5, PTPN7, PTPN1 | CYP2C19 4108/4885CYP3A4 4098/4885SMN1; SMN2 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.